– FRANCE, Nantes – OSE Immunotherapeutics SA (EPA: OSE) today announced the appointment of Dr. Nicolas Poirier as the new CEO, effective immediately, replacing Alexis Vandier whose mandate has been terminated by the Board of Directors.
“Since the creation of OSE Immunotherapeutics in 2016, Nicolas’ world-class scientific expertise, along with his well-recognized human and leadership skills have been vital in the development of the Company, guiding the advancement from the identification of new therapeutic targets into the development of new drugs for severe diseases with a strong medical need. He has been essential in building our diversified portfolio of first-in-class products. He has been able to convince leading scientific experts and our pharmaceutical partners of the value of our innovations. Nicolas’ leadership will allow OSE Immunotherapeutics to accelerate the implementation of our strategic priorities and to achieve new growth milestones,” said Dominique Costantini, President of OSE Immunotherapeutics.
About Dr. Nicolas Poirier
Throughout his career, Dr. Nicolas Poirier has demonstrated both his expertise as an international scientific leader, pioneering the discovery and development of innovative immunotherapies, and in-depth knowledge of the biotech sector through various strategic leadership roles. He has been instrumental in the development of OSE Immunotherapeutics, notably as the initiator of 5 programs in the Company’s portfolio that are now in clinical stage. He also played a major role in the signature of 4 strategic pharmaceutical partnerships for OSE Immunotherapeutics.
Nicolas Poirier, CEO said: “I am very honored to be appointed CEO and would like to thank the Board of Directors for placing their trust in me at a key stage of the Company’s development. I am proud of the work accomplished by our teams, all of whom are focused on advancing our late-stage clinical development programs and high-potential research platforms. I am deeply convinced that OSE Immunotherapeutics’ assets will be able to transform the care of patients suffering from cancer and chronic inflammatory diseases.”
Nicolas Poirier holds a Ph.D. in Immunology (European Center for Transplantation and Immunotherapy Sciences, Nantes), a double master’s degree in Biotechnology from the University of Nantes and in Pharmacology from the University of Louis Pasteur in Strasbourg and certification in Global Management from INSEAD.
Nicolas Poirier has been CSO and member of the management team of OSE Immunotherapeutics since 2016. He started his career at Tcl Pharma in 2009 as a researcher, became Project Manager at Effimune in 2012, then Director of R&D programs in 2014. In addition, Nicolas Poirier in an active member of the Strategic and Scientific Advisory Committee (COSSF) of the French biomedical industry association (MabDesign). Over the past fifteen years, he has authored more than 50 peer-reviewed international scientific publications and holds over 40 issued patents in the field of immunotherapy. Nicolas Poirier and his team have obtained more than 45 million euros in French and European public funding to co-finance OSE Immunotherapeutics’ research and development programs.
About OSE Immunotherapeutics
OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology and immuno-inflammation.
OSE Immunotherapeutics expects to generate further significant value from its two proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapeutics:
BiCKI® platform focused on immuno-oncology (IO) is a bispecific fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target to increase anti-tumor efficacy. The most advanced BiCKI® candidate is targeting anti-PD1xIL-7.
Myeloid platform focused on optimizing the therapeutic potential of myeloid cells in IO and immuno-inflammation (I&I). OSE-230 (ChemR23 agonist mAb) is the most advanced candidate generated by the platform, with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.
OSE Immunotherapeutics expects to generate further significant value from its two proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapeutics:
BiCKI® platform focused on immuno-oncology (IO) is a bispecific fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target to increase anti-tumor efficacy. The most advanced BiCKI® candidate is targeting anti-PD1xIL-7.
Myeloid platform focused on optimizing the therapeutic potential of myeloid cells in IO and immuno-inflammation (I&I). OSE-230 (ChemR23 agonist mAb) is the most advanced candidate generated by the platform, with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.
For more information, visit www.ose-immuno.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.